Stock News•1 week ago
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
Gilead Sciences expanded its oncology pipeline via a Vir Biotechnology deal worth up to $1.74B in additional milestones, targeting three novel cancer therapies.
MarketLens
Why Did Gilead Pay $7.8 Billion for Arcellx
8 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
Why Did GSK Pay $10.6 Billion for Nuvalent
4 months ago
Category
You may also like
Stock News•3 weeks ago
Caribou Biosciences to Evaluate Strategic Alternatives
Caribou Biosciences will evaluate strategic alternatives and discontinue its vispa-cel and CB-011 allogeneic CAR-T programs, a move aimed at maximizing stockholder value.
Stock News•3 months ago
Breakfast News: Vertex Bets $10B to Win $5B a Year
Vertex acquired Crinetics for ~$10B, targeting a potential $5B annual revenue opportunity in endocrine therapies.
Breaking News
View All →Featured Articles
Top Headlines
Stock News•59 minutes ago
Jim Cramer sees major implications from SK Hynix's home-run quarter
Stock News•1 hour ago
Google parent Alphabet tumbles after profit disappoints, warns AI is battering its cash flow
Stock News•1 hour ago
Jim Cramer says these tech giants can weather market turbulence
Stock News•1 hour ago
Alphabet Inc. (GOOG) Misses Q3 Earnings and Revenue Estimates
Stock News•1 hour ago